FDA Determines Regulatory Review Period for TEGSEDI Patent Extension Application

Summary

The U.S. Food and Drug Administration (FDA) has officially confirmed the regulatory review period for TEGSEDI, a human drug product, following the submission of a patent extension application to the U.S. Patent and Trademark Office (USPTO). This determination is a result of the FDA's legal obligation to publish the notice as required by law.